These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27710979)

  • 61. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 62. The future of combination treatment with checkpoint inhibitors in melanoma.
    Sullivan RJ
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
    [No Abstract]   [Full Text] [Related]  

  • 63. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
    Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
    Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
    [No Abstract]   [Full Text] [Related]  

  • 64. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
    Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
    J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
    [No Abstract]   [Full Text] [Related]  

  • 65. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.
    Moncrieff M; Fadhil M; Garioch J
    Br J Dermatol; 2016 May; 174(5):1141-2. PubMed ID: 26598951
    [No Abstract]   [Full Text] [Related]  

  • 66. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.
    Ishida Y; Otsuka A; Tanaka H; Levesque MP; Dummer R; Kabashima K
    J Invest Dermatol; 2017 Nov; 137(11):2443-2444. PubMed ID: 28736235
    [No Abstract]   [Full Text] [Related]  

  • 67. The intralesional interleukin-2 is an adequate palliative treatment in cutaneous metastases of melanoma.
    Menis D; Monsalvez-Honrubia V; Maroñas-Jiménez L; Morales-Raya C; Ortiz-Romero PL
    G Ital Dermatol Venereol; 2017 Aug; 152(4):400-401. PubMed ID: 28621122
    [No Abstract]   [Full Text] [Related]  

  • 68. Malignant melanoma: sex differences in response to chemotherapy?
    Rampen FH
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):107-10. PubMed ID: 7200889
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pathways in melanoma development.
    Erlich TH; Fisher DE
    G Ital Dermatol Venereol; 2018 Feb; 153(1):68-76. PubMed ID: 29319276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity.
    Price LA
    Cancer Treat Rev; 1987 Dec; 14(3-4):215-23. PubMed ID: 3440249
    [No Abstract]   [Full Text] [Related]  

  • 71. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
    Lokich J
    Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
    [No Abstract]   [Full Text] [Related]  

  • 72. Opportunities and challenges in the development of experimental drug combinations for cancer.
    Humphrey RW; Brockway-Lunardi LM; Bonk DT; Dohoney KM; Doroshow JH; Meech SJ; Ratain MJ; Topalian SL; Pardoll DM
    J Natl Cancer Inst; 2011 Aug; 103(16):1222-6. PubMed ID: 21765011
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Do β-blockers slow down melanoma progression?
    Lens M
    Arch Intern Med; 2011 Oct; 171(18):1686-7; author reply 1687. PubMed ID: 21987205
    [No Abstract]   [Full Text] [Related]  

  • 74. Opioids and dose-related deaths--association or causation?
    Williamson OD
    Arch Intern Med; 2011 Oct; 171(18):1687-8; author's reply 1688-9. PubMed ID: 21987206
    [No Abstract]   [Full Text] [Related]  

  • 75. Melanoma: a new landmark in targeted oncology.
    Morère JF
    Target Oncol; 2011 Sep; 6(3):131. PubMed ID: 21858472
    [No Abstract]   [Full Text] [Related]  

  • 76. Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
    Zaremba A; Jansen P; Murali R; Mayakonda A; Riedel A; Krahl D; Burkhardt H; John S; Géraud C; Philip M; Kretz J; Möller I; Stadtler N; Sucker A; Paschen A; Ugurel S; Zimmer L; Livingstone E; Horn S; Plass C; Schadendorf D; Hadaschik E; Lutsik P; Griewank K
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.
    Oncol Res Treat; 2016; 39(10):652-654. PubMed ID: 27710979
    [No Abstract]   [Full Text] [Related]  

  • 78. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
    Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
    Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Severe rash associated with vemurafenib administration following nivolumab therapy.
    Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e84-e86. PubMed ID: 26372833
    [No Abstract]   [Full Text] [Related]  

  • 80. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
    Plummer R; Lorigan P; Steven N; Scott L; Middleton MR; Wilson RH; Mulligan E; Curtin N; Wang D; Dewji R; Abbattista A; Gallo J; Calvert H
    Cancer Chemother Pharmacol; 2013 May; 71(5):1191-9. PubMed ID: 23423489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.